However, other tumor types, including melanoma, glioma, and breast cancer, maintain intact TGFβ signaling but become less responsive to TGFβ-mediated growth suppression through the acquisition of compound oncogenic mutations4,8. This evidence concerns the gene TGFB1 and neoplasm.